Hepatorenal Syndrome (HRS): A Complete Guide

1. Definition and Overview

• Occurs in ~10-30% of hospitalized cirrhotics with ascites
• Annual frequency in cirrhotics with ascites: ~8% (some reports up to 40%)
• Develops in ~30% of cirrhotics admitted with SBP, ~25% with severe alcoholic hepatitis, ~10% requiring serial large-volume paracenteses

2. Pathophysiology

Component 1: Splanchnic and Systemic Arterial Vasodilation

• Portal hypertension drives release of vasodilatory mediators: nitric oxide (NO), carbon monoxide, glucagon, prostacyclin, adrenomedullin, and endogenous opiates
• These cause intense splanchnic and peripheral vasodilation
• Effective circulating blood volume drops, blood pressure falls
• Early: increased heart rate and cardiac output compensate (hyperdynamic circulation)
• Late: compensatory mechanisms become exhausted

Component 2: Counter-regulatory Vasoconstriction (Renal)

• The body perceives decreased effective circulatory volume and activates:
  • Renin-angiotensin-aldosterone system (RAAS)
  • Sympathetic nervous system (SNS)
  • Non-osmotic release of ADH/vasopressin
• These counteract systemic vasodilation but cause paradoxical renal vasoconstriction
• Altered local renal mediators (endothelins, prostaglandins, kallikreins) also contribute
• Result: markedly increased renal vascular resistance, decreased renal perfusion, fall in GFR
• With prolonged intense vasoconstriction, tubular damage can evolve - HRS shifts from functional to organic disease

Component 3: Cardiac Dysfunction (Cirrhotic Cardiomyopathy - CCM)

• Chronic cirrhosis impairs cardiac contractile reserve
• CCM worsens the mismatch between systemic vasodilation and cardiac output
• Contributes to further reduction in effective arterial blood volume

Precipitating Triggers

3. Classification: HRS-AKI vs. HRS-CKD

4. Diagnostic Criteria (ICA 2015 Revised)

1. Cirrhosis with ascites
2. AKI by ICA-AKI criteria: Rise in serum creatinine ≥0.3 mg/dL within 48 h, OR ≥50% rise from baseline within 7 days
3. No response after at least 2 days of: (a) diuretic withdrawal, AND (b) volume expansion with albumin 1 g/kg/day (max 100 g/day)
4. Absence of shock
5. No current or recent nephrotoxic drugs (NSAIDs, aminoglycosides, iodinated contrast)
6. No parenchymal kidney disease: proteinuria <500 mg/day, no microhematuria (>50 RBC/hpf), normal renal ultrasound

AKI Staging in Cirrhosis

Key caveat: Muscle mass and urea synthesis are reduced in cirrhotic patients - serum creatinine may be deceptively low. Even small creatinine rises carry significance and require prompt attention.

5. Clinical Features

• Often asymptomatic in early stages
• Decreased urine output (oliguria nearly universal in HRS-AKI)
• Worsening ascites (often refractory to diuretics)
• Hyponatremia (almost always present)
• Low arterial blood pressure
• Hepatic encephalopathy may be the first presenting sign
• Jaundice, coagulopathy (markers of underlying liver failure)
• Features of precipitating cause (e.g., SBP signs)

• Urine sodium very low (<10 mEq/L) - sodium avid state
• Urine osmolality > plasma osmolality
• No proteinuria or hematuria (distinguishes from glomerular disease)
• Bland urinary sediment

6. Differential Diagnosis of AKI in Cirrhosis

7. Epidemiology and Risk Factors

• Dilutional hyponatremia
• Impaired systemic hemodynamics: high plasma renin activity, elevated noradrenaline, low cardiac output
• Abnormal renal duplex Doppler ultrasound: resistive index >0.7
• Low GFR at baseline

8. Prevention

• Avoid intravascular volume depletion: judicious diuretic use, correct diarrhea from lactulose promptly, always give albumin with large-volume paracentesis
• Large-volume paracentesis: always give IV albumin 6-8 g per liter of ascites removed (prevents post-paracentesis circulatory dysfunction)
• SBP: administer IV albumin (1.5 g/kg on day 1, 1 g/kg on day 3) - reduces HRS development and improves survival
• Norfloxacin prophylaxis: in patients with low ascitic protein (<1.5 g/dL) and either Child-Pugh ≥9 with bilirubin ≥3 mg/dL, or renal impairment (creatinine ≥1.2, BUN ≥25, or Na ≤130) - reduces HRS risk
• Pentoxifylline in severe alcoholic hepatitis (reduces TNF-alpha mediated renal vasoconstriction)
• Avoid nephrotoxins: NSAIDs, ACEIs, ARBs, aminoglycosides
• Treat infections promptly: SBP, bacteremia, sepsis

9. Treatment

Step 1: General Measures (All Patients)

1. Stop all nephrotoxic agents: diuretics, NSAIDs, ACEIs, ARBs, aminoglycosides
2. Treat infections: antibiotics for SBP, sepsis
3. IV albumin bolus: 1 g/kg/day (max 100 g/day) for minimum 2 days
   • If no response after 48 h of albumin + diuretic withdrawal, HRS-AKI diagnosis is confirmed
   • Continue albumin at 20-60 g/day to maintain CVP 10-15 cm H₂O

Step 2: Vasoconstrictor Therapy

First-line: Terlipressin + Albumin (preferred where available)

• Selective vasopressin V1 receptor agonist; approved in Europe; FDA-approved in the USA since 2022
• Dosing: Start 1 mg IV every 4 hr; increase to 2 mg IV every 4 hr if creatinine does not fall ≥25% by day 3
• Also can be given as continuous IV infusion (better tolerated, requires lower doses)
• Efficacy: reverses HRS in 27-43% vs. 8-13% with albumin alone (OT-0401 and REVERSE trials)
• Best response in patients with lower baseline creatinine and lower bilirubin - supports early initiation
• Side effects: cardiovascular complications (ischemia), fluid overload - requires close monitoring
• Duration: maximum 2 weeks, until HRS reverses or LT is performed

Second-line: Norepinephrine + Albumin (ICU, widely available)

• Dosing: 0.1-0.7 μg/kg/min IV infusion; increase by 0.05 μg/kg/min every 4 hr; titrate to MAP increase of ≥10 mmHg
• Efficacy comparable to terlipressin in small RCTs; requires ICU monitoring
• Advantage: widely available and less expensive

Third-line: Midodrine + Octreotide + Albumin (outpatient feasible)

• Used commonly in the USA (historically, before terlipressin approval); now considered third-line
• Midodrine (α₁-adrenergic agonist, oral): start 2.5-5 mg PO TID; increase to max 15 mg TID; titrate to MAP increase ≥15 mmHg
• Octreotide (somatostatin analog - inhibits endogenous vasodilators): 100 μg SC TID to max 200 μg SC TID; or 25 μg IV bolus then 25 μg/hr infusion
• In head-to-head RCT: terlipressin was significantly superior (70.4% recovery vs. 28.6%)

Step 3: Renal Replacement Therapy (RRT)

• If medical treatment fails, RRT (hemodialysis) can be initiated as a bridge to liver transplantation
• Not a definitive therapy; does not address the underlying hepatic dysfunction
• Decision to initiate must weigh transplant candidacy and prognosis

Step 4: TIPS (Transjugular Intrahepatic Portosystemic Shunt)

• Reduces portal hypertension and, secondarily, splanchnic vasodilation
• May improve renal function in carefully selected patients
• Limited evidence; primarily a bridge to LT
• Contraindicated in severe hepatic encephalopathy, advanced hepatic failure (bilirubin >5 mg/dL, Child-Pugh >13)

Step 5: Liver Transplantation (Definitive Therapy)

• The only cure for HRS
• Recovery of renal function is typical after LT
• Patients with combined HRS-AKI or HRS-CKD have poor prognosis unless transplant is achieved
• MELD score incorporates creatinine, bilirubin, and INR - patients with HRS naturally receive high MELD scores, prioritizing them for LT
• Simultaneous liver-kidney transplantation (SLKT) considered when renal recovery after LT is unlikely (prolonged AKI >4-6 weeks)

10. Prognosis

• With vasoconstrictor treatment: reversal in 27-43% (terlipressin)
• Even after reversal, recurrence is high unless LT is performed
• Liver transplantation markedly improves survival; renal function typically recovers
• The kidney, when transplanted into a non-cirrhotic recipient, functions normally - confirming the purely functional nature of HRS

11. Recent Evidence (2024-2026)

12. Quick Clinical Summary

Suspect HRS when:
  Cirrhotic patient + ascites + rising creatinine

Rule out:
  Volume depletion → Give albumin 1 g/kg/day x 2 days
  Nephrotoxins → Stop diuretics, NSAIDs, ACEIs, ARBs
  Infection → Check ascites (SBP), blood cultures
  ATN/glomerular disease → Urine sediment, protein, imaging

If no response to albumin challenge → HRS-AKI confirmed

Treat:
  1st: Terlipressin + albumin
  2nd: Norepinephrine + albumin (ICU)
  3rd: Midodrine + Octreotide + albumin
  Bridge: RRT, TIPS
  Definitive: Liver Transplantation

Prevent:
  Albumin with LVP, treat SBP with albumin,
  norfloxacin prophylaxis in high-risk patients,
  avoid nephrotoxins